Deal would further strengthen Watson-Actavis' Asian position
This article was originally published in Scrip
Executive Summary
Any global merger between Watson Pharmaceuticals and Actavis would give the combined group a stronger position in the critical established and emerging markets of Asia, where the Swiss-based firm and more recently its US rival have been steadily building up their operations